Dermira, Inc. DERM was a big mover last session, as the company saw its shares rise nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 86.2% in the past one-month time frame.
The move came following reports that a Citi analyst has raised the one-year target price for the company, citing positive phase 2b results for lebrikizumab. The biopharmaceutical company also announced the pricing of its underwritten public offering worth $130 million.
The company has seen a mixed track record when it comes to estimate revision of no increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn't been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Dermira currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Dermira, Inc. Price
Dermira, Inc. Price | Dermira, Inc. Quote
Investors interested in the Medical - Drugs industry may consider AIT Therapeutics, Inc. AITB , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is DERM going up? Or down? Predict to see what others think: Up or Down
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dermira, Inc. (DERM): Free Stock Analysis Report AIT Therapeutics, Inc. (AITB): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research